Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Gains from Sales and Divestitures (2016 - 2018)

Historic Gains from Sales and Divestitures for Alaunos Therapeutics (TCRT) over the last 8 years, with Q3 2018 value amounting to $573340.0.

  • Alaunos Therapeutics' Gains from Sales and Divestitures rose 6381.14% to $573340.0 in Q3 2018 from the same period last year, while for Sep 2018 it was $573340.0, marking a year-over-year increase of 6381.14%. This contributed to the annual value of $778965.0 for FY2017, which is 2611.43% up from last year.
  • Alaunos Therapeutics' Gains from Sales and Divestitures amounted to $573340.0 in Q3 2018, which was up 6381.14% from $538824.0 recorded in Q2 2018.
  • Alaunos Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $778965.0 during Q4 2017, with a 5-year trough of $48433.0 in Q1 2014.
  • Over the past 5 years, Alaunos Therapeutics' median Gains from Sales and Divestitures value was $253835.0 (recorded in 2014), while the average stood at $285443.0.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first tumbled by 6510.94% in 2014, then surged by 39302.02% in 2016.
  • Alaunos Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $253835.0 in 2014, then plummeted by 41.42% to $148694.0 in 2015, then soared by 315.39% to $617666.0 in 2016, then rose by 26.11% to $778965.0 in 2017, then fell by 26.4% to $573340.0 in 2018.
  • Its Gains from Sales and Divestitures was $573340.0 in Q3 2018, compared to $538824.0 in Q2 2018 and $205491.0 in Q1 2018.